Home/Pipeline/Project 3

Project 3

HER2-positive advanced solid tumors

Phase IActive

Key Facts

Indication
HER2-positive advanced solid tumors
Phase
Phase I
Status
Active
Company

About Suzhou Teligene

Clinical-stage Chinese biotech developing brain-penetrant small molecule targeted therapies for oncology, with multiple programs in Phase I-II trials.

View full company profile

Therapeutic Areas

Other HER2-positive advanced solid tumors Drugs

DrugCompanyPhase
Project 7Suzhou TeligeneIND Submitted